neovax
Vaccineexperimental
Clinical trial activity
7 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2016 (NCT02950766)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- neovax
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04930783 | Phase 1 | Nov 30, 2021 | Celldex Therapeutics, Harvard University |
| NCT04024878 | Phase 1 | Sep 1, 2019 | Department of Defense, Harvard University |
| NCT03929029 | Phase 1 | Jun 1, 2019 | Harvard University, National Cancer Institute (NCI) |
| NCT03422094 | Phase 1 | Sep 30, 2018 | Washington University in St. Louis |
| NCT03219450 | Phase 1 | Sep 1, 2018 | Harvard University, Neon Therapeutics, Oncovir, Inc. |
| NCT03361852 | Phase 1 | Jul 1, 2018 | Harvard University |
| NCT02950766 | Phase 1 | Oct 1, 2016 | Bristol-Myers Squibb, Harvard University, Oncovir, Inc. |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Harvard University | Academic/Hospital | 6 | 6 | 1 | 2016 |
| Oncovir, Inc. | For profit | 2 | 0 | 1 | 2016 |
| Bristol-Myers Squibb | For profit | 1 | 0 | 1 | 2016 |
| Celldex Therapeutics | For profit | 1 | 0 | 1 | 2021 |
| Department of Defense | Government | 1 | 0 | 1 | 2019 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2019 |
| Neon Therapeutics | For profit | 1 | 0 | 1 | 2018 |
| Washington University in St. Louis | Academic/Hospital | 1 | 1 | 1 | 2018 |
8 organizations
Page 1 / 1